Miruvor
Sign up
The short answer

What studies of Favipiravir (Avigan) found

4papers on Favipiravir (Avigan)
712people in 1 study testing Favipiravir (Avigan) alone
0randomised trials, the strongest kind of study

At a glance, by condition

Preventing long COVID: D Little or no difference

Based on the strongest evidence, compared with another group, not randomised (very low certainty): 4 findings, all D.

4 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Studies found little or no difference with Favipiravir (Avigan) for preventing long COVID. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 4 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. C
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. Favipiravir (Avigan) · Preventing long COVID is hereD
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Preventing long COVID

Cognition (brain fog)1 study · 712 people took Favipiravir (Avigan) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance.

Compared with another group, not randomised712 in the study · 60 days after onset/diagnosis · 1600 mg of loading doses ... followed by 600 mg every 12 h from day 2–5, every 12 h on the first day, then every 12 h from day 2–5

No clear difference in cognition (brain fog).

The evidence is very uncertain about the effect of favipiravir (Avigan) on cognition (brain fog) later, when given during acute COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance
See the 1 study
  1. Post-COVID depression and its multiple factors, does Favipiravir have a protective effect? A longitudinal study of indonesia COVID-19 patients. (2022)

    People in the study
    712 in the study
    Dose
    1600 mg of loading doses ... followed by 600 mg every 12 h from day 2–5, every 12 h on the first day, then every 12 h from day 2–5
    Outcome
    Concentration Patient Health Questionnaire 9 (PHQ-9)
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: propensity-matched selection from the primary cohort (age, sex, occupation, island of origin, self-reported allergy, hypersensitivity; tolerance 0.05) VariablesBSEdfSig.Exp(B)95.0% CI for Exp(B)LowerUpperAge−.002.0091.786.998.9801.015Male (Female as reference).115.1881.5411.122.7761.622Living alone.352.1861.0591.422.9872.048
    Selection of participants
    Moderate. comparison group: propensity-matched selection from the primary cohort (age, sex, occupation, island of origin, self-reported allergy, hypersensitivity; tolerance 0.05) we performed propensity match selection and allocated the participants equally to obtain an unbiased cohort
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Follow-up not extended because of low response rate; no imputation needed for baseline data We did not extend the follow-up period because of the low response rate in the following weeks.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
Depression1 study · 712 people took Favipiravir (Avigan) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance.

Compared with another group, not randomised712 in the study · 60 days after onset/diagnosis · 1600 mg of loading doses ... followed by 600 mg every 12 h from day 2–5, every 12 h on the first day, then every 12 h from day 2–5

No clear difference in depression.

The evidence is very uncertain about the effect of favipiravir (Avigan) on depression later, when given during acute COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance
See the 1 study
  1. Post-COVID depression and its multiple factors, does Favipiravir have a protective effect? A longitudinal study of indonesia COVID-19 patients. (2022)

    People in the study
    712 in the study
    Dose
    1600 mg of loading doses ... followed by 600 mg every 12 h from day 2–5, every 12 h on the first day, then every 12 h from day 2–5
    Outcome
    Depression within 60 days Patient Health Questionnaire 9 (PHQ-9)
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: propensity-matched selection from the primary cohort (age, sex, occupation, island of origin, self-reported allergy, hypersensitivity; tolerance 0.05) VariablesBSEdfSig.Exp(B)95.0% CI for Exp(B)LowerUpperAge−.002.0091.786.998.9801.015Male (Female as reference).115.1881.5411.122.7761.622Living alone.352.1861.0591.422.9872.048
    Selection of participants
    Moderate. comparison group: propensity-matched selection from the primary cohort (age, sex, occupation, island of origin, self-reported allergy, hypersensitivity; tolerance 0.05) we performed propensity match selection and allocated the participants equally to obtain an unbiased cohort
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Follow-up not extended because of low response rate; no imputation needed for baseline data We did not extend the follow-up period because of the low response rate in the following weeks.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Low. a pre-specified primary outcome in a registered study
Fatigue1 study · 712 people took Favipiravir (Avigan) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance.

Compared with another group, not randomised712 in the study · 60 days after onset/diagnosis · 1600 mg of loading doses ... followed by 600 mg every 12 h from day 2–5, every 12 h on the first day, then every 12 h from day 2–5

No clear difference in fatigue.

The evidence is very uncertain about the effect of favipiravir (Avigan) on fatigue later, when given during acute COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance
See the 1 study
  1. Post-COVID depression and its multiple factors, does Favipiravir have a protective effect? A longitudinal study of indonesia COVID-19 patients. (2022)

    People in the study
    712 in the study
    Dose
    1600 mg of loading doses ... followed by 600 mg every 12 h from day 2–5, every 12 h on the first day, then every 12 h from day 2–5
    Outcome
    Fatigue Patient Health Questionnaire 9 (PHQ-9)
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: propensity-matched selection from the primary cohort (age, sex, occupation, island of origin, self-reported allergy, hypersensitivity; tolerance 0.05) VariablesBSEdfSig.Exp(B)95.0% CI for Exp(B)LowerUpperAge−.002.0091.786.998.9801.015Male (Female as reference).115.1881.5411.122.7761.622Living alone.352.1861.0591.422.9872.048
    Selection of participants
    Moderate. comparison group: propensity-matched selection from the primary cohort (age, sex, occupation, island of origin, self-reported allergy, hypersensitivity; tolerance 0.05) we performed propensity match selection and allocated the participants equally to obtain an unbiased cohort
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Follow-up not extended because of low response rate; no imputation needed for baseline data We did not extend the follow-up period because of the low response rate in the following weeks.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
Sleep1 study · 712 people took Favipiravir (Avigan) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance.

Compared with another group, not randomised712 in the study · 60 days after onset/diagnosis · 1600 mg of loading doses ... followed by 600 mg every 12 h from day 2–5, every 12 h on the first day, then every 12 h from day 2–5

No clear difference in sleep.

The evidence is very uncertain about the effect of favipiravir (Avigan) on sleep later, when given during acute COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance
See the 1 study
  1. Post-COVID depression and its multiple factors, does Favipiravir have a protective effect? A longitudinal study of indonesia COVID-19 patients. (2022)

    People in the study
    712 in the study
    Dose
    1600 mg of loading doses ... followed by 600 mg every 12 h from day 2–5, every 12 h on the first day, then every 12 h from day 2–5
    Outcome
    Sleep disorders Patient Health Questionnaire 9 (PHQ-9)
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: propensity-matched selection from the primary cohort (age, sex, occupation, island of origin, self-reported allergy, hypersensitivity; tolerance 0.05) VariablesBSEdfSig.Exp(B)95.0% CI for Exp(B)LowerUpperAge−.002.0091.786.998.9801.015Male (Female as reference).115.1881.5411.122.7761.622Living alone.352.1861.0591.422.9872.048
    Selection of participants
    Moderate. comparison group: propensity-matched selection from the primary cohort (age, sex, occupation, island of origin, self-reported allergy, hypersensitivity; tolerance 0.05) we performed propensity match selection and allocated the participants equally to obtain an unbiased cohort
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Follow-up not extended because of low response rate; no imputation needed for baseline data We did not extend the follow-up period because of the low response rate in the following weeks.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported

Side effects

No study of this treatment alone reported side effects we could read.

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    1600 mg at the start

  2. 2Top dose

    Most often 1600 mg (1 of 1 studies)

Doses across 1 study

1600 to 1600 mg.

Each study’s dose, as printed

All papers

  1. Risk factors and early preventive measures for long COVID in non-hospitalized patients: analysis of a large cohort in the United Arab Emirates.2024 · compared with another group · 28,375 in the study
    Summary

    This cohort study asked which patient-specific factors were associated with long COVID and whether pre-COVID vaccination or treatments received during acute COVID-19 were associated with long COVID risk. It included 28,375 non-hospitalized adult patients diagnosed with mild to moderate COVID-19 in Dubai between January 1, 2021, and September 31, 2022, who were followed up for 90 days. The presence of long COVID symptoms was documented by physicians during patient visits to the family medicine department. The abstract reports that pre-COVID vaccination was associated with a reduced risk of long COVID in all patient subgroups. It also reports that treatment with favipiravir or sotrovimab during the acute phase of COVID-19 was linked to a decreased risk of long COVID, although the abstract notes a limit for favipiravir in the high-risk group. Doses and treatment duration are not reported. The abstract reports no side effects, harms, or withdrawals due to harms for any arm. The authors conclude that the study identifies risk factors for long COVID among non-hospitalized patients and emphasizes the potential benefits of pre-COVID vaccination and timely treatment. The abstract does not state limitations.

  2. Post-COVID depression and its multiple factors, does Favipiravir have a protective effect? A longitudinal study of indonesia COVID-19 patients.2022 · compared with another group · 712 in the study
    Summary

    This cohort study used an Indonesian online post-COVID survey of patients diagnosed with COVID-19 from all provinces. It extracted 712 participants and used propensity matching to allocate them 1:1 to a favipiravir group or a nonrecipient group. Favipiravir was given orally as 1600 mg loading doses every 12 h on the first day, followed by 600 mg every 12 h from day 2–5. The nonrecipient group was people whose disease resolved without any other antiviral medications. The outcome was depression measured with the Patient Health Questionnaire 9 (PHQ-9), with follow-up for 60 days after onset/diagnosis. Within 60 days of follow-up, 57 people (16.01%) in the favipiravir group developed depression, compared with 75 (21.06%) in the nonrecipient group. The bivariate difference was nonsignificant (crude OR 0.71, 95% CI 0.49–1.05, p = 0.089). In Cox regression, favipiravir administration was associated with post-COVID depression (aOR 0.488, 95% CI 0.339–0.701, p < 0.001). Favipiravir showed a protective effect for depressive mood (aOR 0.378, 95% CI 0.195–0.731, p = 0.004) and loss of interest/anhedonia (aOR 0.543, 95% CI 0.326–0.906, p = 0.019), but not for sleep disorders, concentration, or fatigue. Harms and withdrawals were not reported. The authors state the data were self-reported and that follow-up was not extended because of low response rate.

  3. Vaccination status, favipiravir, and micronutrient supplementation roles in post-COVID symptoms: A longitudinal study.2022 · compared with another group · 923 in the study
    Summary

    This longitudinal survey followed recovered COVID-19 patients from Indonesia who were diagnosed by PCR/antigen testing and had recovered less than 30 days after onset. A total of 923 participants’ data were extracted; 168 people were fully vaccinated more than 14 days after a second dose, 41 had received one dose, and 713 were unvaccinated at diagnosis. Participants reported post-COVID symptoms every 30 days for a total of 90 days after onset or diagnosis. The study compared fully vaccinated participants with those who had one dose or were unvaccinated, and compared timing of Favipiravir, vitamin C, vitamin D, and zinc with early initiation or no treatment. For any post-COVID symptoms in 90 days, there was no difference between fully vaccinated and incomplete or unvaccinated individuals after adjustment (aOR 0.74, 95% CI 0.51–1.08, p = 0.118). Complete vaccination was associated with lower odds of chronic cough (aOR 0.527, 95% CI 0.286–0.971, p = 0.040), chronic headache (aOR 0.317, 95% CI 0.163–0.616, p = 0.001), and chronic arthritis (aOR 0.285, 95% CI 0.116–0.703, p = 0.006). Not taking Favipiravir was associated with lower odds of arthritis than taking it within 24 hours (aOR 0.503, 95% CI 0.287–0.882, p = 0.017). Vitamin C later than 72 hours was associated with lower odds of the overall event than vitamin C within 24 hours (aOR 0.63, 95% CI 0.39–0.99, p = 0.048). The combination of micronutrient supplementations and Favipiravir gave no significant effect in seven outcomes. Harms were not reported for this cohort.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime